What is the BiotechSign catalyst score for HRMY?

HRMY currently has a BiotechSign catalyst score of 77/100 and grade B. Scores combine FDA, clinical trial, insider, dilution, sentiment, short interest, and convergence signals.

What signals does BiotechSign track for HRMY?

BiotechSign tracks 0 active signals for HRMY, including 0 PDUFA signals, 0 insider buying signals, and 0 clinical trial signals when available.

When was the HRMY catalyst page updated?

This HRMY page was refreshed from BiotechSign data on 2026-07-19.

You have used your free lookups for today

Upgrade to BiotechSign Pro for unlimited company access, full signal history, watchlist alerts, and 125+ PDUFA dates.

Upgrade to Pro →← Back to screener

← Back to Screener

HRMY — Harmony Biosciences

Harmony Biosciences

NeuroscienceScore: 77/100Full Profile

What is the current HRMY catalyst setup?

HRMY is tracked by BiotechSign with a current catalyst score of 77/100 and grade B. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.

Company SnapshotUpdated 2026-07-19

As of 2026-07-19, Harmony Biosciences (HRMY) has a BiotechSign Catalyst Score of 77/100, rated B. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.

This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).

Analyst Summary

Verified 2026-04-11

Harmony Biosciences (HRMY) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov^[3], including 3 Phase 3^[1], 1 Phase 2^[2].

Trial NCT07219485^[4] evaluates Pitolisant in Prader-Willi Syndrome with a target enrollment of 150 participants. Trial NCT07500090^[5] evaluates HBS-301 tablet in Idiopathic Hypersomnia with a target enrollment of 248 participants. Trial NCT06366464^[6] evaluates Pitolisant tablet in Prader-Willi Syndrome with a target enrollment of 134 participants.

HRMY has 3 Form 4 insider filings recorded at the SEC in the past 30 days^[7].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov · NCT07219485 (2026-03-17) ↗
ClinicalTrials.gov · NCT07500090 (2026-03-30) ↗
ClinicalTrials.gov · NCT06366464 (2026-03-17) ↗
SEC EDGAR · 0001802665 (2026-04-11) ↗

Not financial advice. BiotechSign scores are for informational purposes only and do not constitute investment recommendations. Always do your own due diligence before making investment decisions.